AstraZeneca stock: Q3 growth holds 2026 outlook steady

AstraZeneca's nine-month and third-quarter results, published on October 30, showed continued commercial momentum while management kept its full-year 2026 outlook unchanged. The company reported total revenue of 46.881 billion US dollars for the first nine months, up 7 percent at constant exchange rates, while core earnings per share rose 14 percent to 8.00 US dollars, according to the AstraZeneca results release.

AstraZeneca stock traded at 164.93 euros on Lang & Schwarz at 17:50 CET on Tuesday, November 3, 2026. The real-time quote of AstraZeneca stock is available separately.

Growth remains concentrated in key areas

Oncology revenue increased 16 percent at constant exchange rates to 21.889 billion US dollars in the first nine months, making it AstraZeneca's largest therapy area. Rare disease revenue rose 11 percent, while the broader biopharmaceuticals category declined 5 percent as loss of exclusivity for Farxiga and Brilinta and procurement pressure in China weighed on performance.

Third-quarter total revenue reached 16.209 billion US dollars, up 7 percent at constant exchange rates. Core earnings per share increased 19 percent at constant exchange rates to 2.79 US dollars. AstraZeneca also reported four new-medicine approvals and 12 positive Phase III readouts in the year to date.

Guidance and investor calendar

The company expects full-year 2026 total revenue to grow by a mid-to-high single-digit percentage at constant exchange rates and core earnings per share by a low double-digit percentage. The core tax rate is expected to remain between 18 and 22 percent. AstraZeneca's investor-relations calendar lists a Berenberg CFO series and a Redburn roadshow for November 9.

The broader UK market backdrop is covered in current FTSE 100 market reports.

More news and analyses on AstraZeneca stock